Search

Nifedipine

[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]

Ropinirole

Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. … Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], [A174547].

Cisatracurium

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate. Cisatracurium has an intermediate duration of action and is one of the most commonly ...

Piracetam

It is not approved for any medical or dietary use by the FDA.

Fulvestrant

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, ...

Bicalutamide

Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen recep...

Benzalkonium

Benzalkonium is more commonly contained in consumer products in its salt form, benzalkonium chloride [FDA Label]. … Benzalkonium is a quaternary ammonium compound used as a biocide, a cationic surfactant, and as a phase transfer agent [FDA Label].

Guanfacine

[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274]

FR-234938